<DOC>
	<DOCNO>NCT01494896</DOCNO>
	<brief_summary>The purpose study see inhale treprostinil sodium ( Tyvaso ) affect amount air blood reach alveolus , tiy air sac , lungs patient Group 1 Pulmonary Arterial Hypertension concomitant Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Impact Inhaled Treprostinil Sodium Ventilation Perfusion Matching</brief_title>
	<detailed_description>In patient severe COPD FEV1 50 % less predict , emphysema obliterate bronchiolitis present `` ceiling '' improvement function achieve therapy dilate airway lessen inflammation . Such severe COPD commonly associate pulmonary hypertension rest exercise . Although hypoxia classically consider major pathogenic mechanism pulmonary hypertension COPD oxygen mainstay therapy , mechanism may play important role . Indeed , endothelial dysfunction observe patient mild moderate COPD hypoxemia smoker normal lung function . In addition , long-term oxygen therapy generally result resolution pulmonary hypertension . A key question remain whether new therapy pulmonary arterial hypertension ( PAH ) could improve pulmonary hypertension therefore exercise tolerance COPD . Unfortunately use non-selective pulmonary vasodilator therapy oral , intravenous subcutaneous form PAH patient unrelated concomitant COPD , know cause worsen gas exchange intensification symptom despite decrease pulmonary vascular resistance arterial pressure . We hypothesize inhaled pulmonary vasodilator may worsen ventilation-perfusion mismatch selectively vasodilating well ventilate area PAH patient concomitant COPD fact may improve ventilation perfusion match leading preservation improvement oxygenation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject diagnosis PAH confirm right heart catheterization within last 12 month ( define mean pulmonary artery pressure great equal 25 pulmonary capillary wedge pressure leave ventricular enddiastolic pressure less equal 15 ) . Subject initiate inhaled treprostinil treatment PAH . Subject 18 80 year age screen diagnosis COPD confirm spirometry within last 6 month show FEV1 &gt; 40 % predict FEV/FVC &lt; 70 . Baseline 6minute walk distance &gt; 150 meter . Subject approve therapy PH last 90 day . If subject treat conventional therapy COPD , must receive fix regimen therapy tat least 30 day prior Baseline . Previous echocardiography evidence normal leave systolic diastolic ventricular function , absence clinically significant leave sided heart disease . If female , physiologically incapable childbearing practice acceptable method birth control deem appropriate physician institution . If female , negative serum pregnancy test require screening . Subject voluntarily give informed consent . The subject pregnant lactating . Subject new type chronic therapy PH add within 90 day Baseline . Subject medication start discontinue COPD within 30 day Baseline . Subject following : portal hypertension , chronic thromboembolic disease , pulmonary venoocclusive disease accept part inclusion criterion atrial septostomy . Subject current diagnosis uncontrolled sleep apnea define physician . Subject history current evidence leftsided heart disease . Subject interstitial lung disease evidence CT scan restrictive pattern pulmonary function test ( FEV1/FVC &gt; 70 TLC &lt; 80 % predict ) COPD FEV1 &lt; 40 % predict . Subject musculoskeletal disorder disease likely limit ambulation , connect machine portable . Subject incapable maintaining compliance throughout course study . Any condition , investigator 's opinion , would constitute unacceptable risk subject 's safety . Subject receive investigational drug , investigational device place participate investigational drug device study within 30 day prior screen . Subjects without telephone contact .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Tyvaso</keyword>
	<keyword>Inhaled Treprostinil Sodium</keyword>
	<keyword>Ventilation Perfusion Matching</keyword>
	<keyword>HO Group 1 Pulmonary Arterial Hypertension</keyword>
	<keyword>Concomitant Chronic Obstructive Pulmonary Disease</keyword>
</DOC>